An inactivated Pseudomonas aeruginosa medicament inhibits airway allergic inflammation and improves epithelial
Yurong Tan1, Huijun Liu1, Huihui Yang1
1Department of Basic Medicine, Xiangya School of Medicine, Central South University, Changsha, 410078, Hunan, China.
Abstract:
The features of asthma are airway hyperresponsiveness (AHR), excess production of Th2 cytokines, and eosinophil accumulation in the lungs. To investigate the antiasthmatic potential of an inactivated Pseudomonas aeruginosa medicament (PPA), as well as the underlying mechanism involved, we studied the effects of PPA on airway and epithelial functions. Airway resistance, cell enumeration, and IL-4, IFN-γ, and IL-17 secretion in bronchoalveolar lavage fluid were assayed on an OVA-sensitized AHR animal model. Flow cytometry was used to observe the effects of PPA on cell proliferation, real-time PCR was used to test the expressions of toll like receptor 4 and 5, and Th17 signal molecules Act1, NF-kB negative regulator A20, and western blot were used to detect NF-kB expression on cultured human bronchial epithelial cells (BECs). PPA-treated animals had suppressed airway resistance, eosinophil and lymphocytes infiltration, and IL-4 and IL-17 secretion. PPA can stimulate toll-like receptor-4 and 5 expressions, promote cell proliferation in normal and OVA-treated BECs, significantly decrease Act1 and NF-kB, and increase A20 expression in BECs treated by OVA. Our data suggest the therapeutic mechanism by which PPA effectively treats allergic inflammation on reductions of airway responsiveness, eosinophil infiltration, IL-4 and IL-17 secretion, and improvements of epithelial functions.
Insights
Inactivated Pseudomonas aeruginosa medicament (PPA) reduces asthma symptoms by decreasing airway hyperresponsiveness, inflammation, and improving epithelial function. PPA targets key inflammatory pathways, offering therapeutic potential for allergic airway diseases.
Area of Science:
- Immunology
- Pulmonology
- Microbiology
Background:
- Asthma is characterized by airway hyperresponsiveness, Th2 cytokine overproduction, and eosinophil lung accumulation.
- Investigating novel therapeutic agents for allergic airway inflammation is crucial.
Purpose of the Study:
- To evaluate the antiasthmatic effects of inactivated Pseudomonas aeruginosa medicament (PPA).
- To elucidate the underlying mechanisms of PPA's action on airway and epithelial functions.
Main Methods:
- An OVA-sensitized animal model was used to assess airway resistance, cell counts, and cytokine secretion (IL-4, IFN-γ, IL-17).
- Flow cytometry, real-time PCR, and western blot analyzed PPA's effects on cell proliferation, TLR expression, and inflammatory signaling pathways (Act1, A20, NF-kB) in bronchial epithelial cells.
Main Results:
- PPA treatment significantly reduced airway resistance, eosinophil and lymphocyte infiltration, and IL-4 and IL-17 levels.
- PPA stimulated Toll-like Receptor 4 and 5 expression.
- PPA promoted bronchial epithelial cell proliferation and modulated inflammatory signaling by decreasing Act1 and NF-kB, while increasing A20 expression.
Conclusions:
- PPA demonstrates significant therapeutic potential for allergic asthma.
- PPA alleviates airway inflammation and hyperresponsiveness by improving epithelial function and modulating inflammatory signaling pathways.
Related Concept Videos
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:23Inhaled Medications
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
01:24Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...